Soy Isoflavones For Inner City Infants At Risk For Asthma (SIRA) Study
NCT05667701
This study is recruiting at 2 US sites in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The goal of this clinical trial is to compare soy isoflavones to placebo in children who at risk of asthma and have a genetic variation which results in them making more of a pro-inflammatory protein, plasminogen activator inhibitor-1. The main questions this trail seeks to answer is: will soy isoflavones decrease the proportion of infants with aT2 high endotype at the end of treatment, and secondarily decrease the number of wheezing episodes in these children when given in the first year of life.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Wheezing
- Asthma in Children
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 2 to 12 months
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Rajesh Kumar
- Last updated on ClinicalTrials.gov
- November 21, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Illinois · 2
- Ann and Robert H Lurie Childrens Hospital of Chicago · Chicago, IL
- Northwestern University Feinberg School of Medicine · Chicago, IL
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.